(NASDAQ: SRDX) Surmodics's forecast annual revenue growth rate of 3.27% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.12%.
Surmodics's revenue in 2025 is $121,575,000.On average, 2 Wall Street analysts forecast SRDX's revenue for 2026 to be $1,751,803,078, with the lowest SRDX revenue forecast at $1,744,653,445, and the highest SRDX revenue forecast at $1,758,952,711.
In 2027, SRDX is forecast to generate $1,853,828,341 in revenue, with the lowest revenue forecast at $1,849,610,057 and the highest revenue forecast at $1,858,046,624.